January 2013 | OncologyLive

BATTLE-2: Next-Generation of Biomarker-Driven Trials

February 08, 2013

While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.

Innovative BATTLE Trials Pair Agents, Biomarkers in NSCLC

February 07, 2013

As therapy based on cell-signaling pathways has become a priority in cancer research, so has the concept of designing clinical trials that can better target patient populations more likely to benefit from a particular regimen.